Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 25, 2026, 8:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 6,716 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Orlando, Florida Clear all
Active, not recruiting Phase 3 Interventional

Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma

NCT00978458
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Neurotoxicity
Interventions
temozolomide, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy
Drug · Radiation
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
168
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 117 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2025 · Synced Jul 25, 2026, 8:20 AM EDT
Completed Not applicable Interventional

Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate

NCT02649478
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone / Salmeterol, Placebo, Advair Diskus 100/50
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
12 Years and older
Enrollment
1,430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
100
States / cities
Glendale, Arizona • Phoenix, Arizona • Surprise, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Jul 25, 2026, 8:20 AM EDT
Completed Phase 2 Interventional Results available

Efficacy Study of Digibind for Treatment of Severe Preeclampsia

NCT00158743
View directory record Official record
Conditions
Pre-eclampsia
Interventions
Anti-digoxin antibody (FAB fragment), sodium chloride
Drug · Other
Lead sponsor
BTG International Inc.
Other
Eligibility
Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
8
States / cities
Mobile, Alabama • Phoenix, Arizona • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2014 · Synced Jul 25, 2026, 8:20 AM EDT
Completed Phase 2 Interventional

Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

NCT01079325
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy
Interventions
SB-509, Saline
Drug · Other
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated May 22, 2022 · Synced Jul 25, 2026, 8:20 AM EDT
Completed Phase 3 Interventional

Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder

NCT01110889
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Agomelatine (AGO178C), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
47
States / cities
Birmingham, Alabama • Beverly Hills, California • Encino, California + 41 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Jul 25, 2026, 8:20 AM EDT
Completed Phase 4 Interventional Results available

EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension

NCT03497689
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Intravenous/Subcutaneous Treprostinil; Oral Treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
11
States / cities
Fresno, California • Torrance, California • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2023 · Synced Jul 25, 2026, 8:20 AM EDT
Completed Phase 2 Interventional

A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis

NCT01483742
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
RO5024048, danoprevir, peginterferon alfa-2a [Pegasys], ribavirin, ritonavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
15
States / cities
Birmingham, Alabama • Anaheim, California • Coronado, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2016 · Synced Jul 25, 2026, 8:20 AM EDT
Completed Not applicable Interventional Results available

Promoting Cancer Symptom Management in Older Adults

NCT03143829
View directory record Official record
Conditions
Neoplasms, Chemotherapy-induced Nausea and Vomiting
Interventions
eSSET-CINV
Other
Lead sponsor
University of Central Florida
Other
Eligibility
65 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 28, 2021 · Synced Jul 25, 2026, 8:20 AM EDT
Terminated Phase 2 Interventional

A Study to Evaluate the Analgesic Efficacy and Safety of VM902A in Subjects With Osteoarthritis (OA) of the Knee

NCT02847702
View directory record Official record
Conditions
Osteoarthritis Pain of the Knee
Interventions
VM902A 200-mg Capsules, VM902A 400-mg Capsules, Naproxen 500-mg Capsules, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
31
States / cities
Birmingham, Alabama • Huntsville, Alabama • DeLand, Florida + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2017 · Synced Jul 25, 2026, 8:20 AM EDT
Terminated No phase listed Observational Results available

ST Segment Detection Study

NCT00930969
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
ICD
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
17
States / cities
Anchorage, Alaska • Brandon, Florida • Orlando, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2019 · Synced Jul 25, 2026, 8:20 AM EDT
Completed Phase 3 Interventional Results available

A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes

NCT02963766
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dulaglutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
10 Years to 17 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
23
States / cities
Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Jul 25, 2026, 8:20 AM EDT
Completed Phase 2 Interventional

Study to Assess Safety, Tolerability and Efficacy of Incremental Doses of MGB-BP-3 in Patients With CDAD

NCT03824795
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
MGB-BP-3
Drug
Lead sponsor
MGB Biopharma Limited
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
8
States / cities
Miami, Florida • Orlando, Florida • Idaho Falls, Idaho + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2020 · Synced Jul 25, 2026, 8:20 AM EDT
Completed Not applicable Interventional Results available

Single Embryo TrAnsfeR of Euploid Embryo

NCT02268786
View directory record Official record
Conditions
Infertility, Aneuploidy
Interventions
Preimplantation Genetic Screening by NGS
Other
Lead sponsor
Illumina, Inc.
Industry
Eligibility
25 Years to 40 Years · Female only
Enrollment
661 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
28
States / cities
Tempe, Arizona • Encino, California • Laguna Niguel, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Jul 25, 2026, 8:20 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

OMILQ: Osteopathic Manipulation to Increase Lactation Quantity (OMILQ)

NCT03875794
View directory record Official record
Conditions
Osteopathic Manipulation
Interventions
Osteopathic Manipulation
Other
Lead sponsor
AdventHealth
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Jul 25, 2026, 8:20 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of AB023 (Xisomab 3G3) in End Stage Renal Disease Patients on Chronic Hemodialysis

NCT03612856
View directory record Official record
Conditions
End Stage Renal Disease, Thrombosis
Interventions
AB023- Dose 1, AB023-Dose 2, placebo
Drug
Lead sponsor
Aronora, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Jul 25, 2026, 8:20 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19

NCT04779879
View directory record Official record
Conditions
Covid19
Interventions
Sotrovimab (Gen1), Sotrovimab (Gen2)
Biological
Lead sponsor
Vir Biotechnology, Inc.
Industry
Eligibility
18 Years to 69 Years
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
18
States / cities
Anniston, Alabama • Bakersfield, California • Northridge, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 2, 2023 · Synced Jul 25, 2026, 8:20 AM EDT
Completed Phase 3 Interventional Results available

Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer

NCT03223753
View directory record Official record
Conditions
Carcinoma In Situ, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Educational Intervention, Internet-Based Intervention, Laboratory Biomarker Analysis, Medical Device Usage and Evaluation, Quality-of-Life Assessment, Questionnaire Administration
Other · Device
Lead sponsor
Children's Oncology Group
Network
Eligibility
8 Years to 16 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
113
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 91 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Jul 25, 2026, 8:20 AM EDT
Completed Phase 2 Interventional Results available

The Use of Rotigotine for Treatment of Reducing Signs and Symptoms of Fibromyalgia in Adults.

NCT00464737
View directory record Official record
Conditions
Fibromyalgia Syndrome
Interventions
Rotigotine, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
35
States / cities
Mobile, Alabama • Mesa, Arizona • Peoria, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2015 · Synced Jul 25, 2026, 8:20 AM EDT
Completed Phase 3 Interventional

A Study of the TAXUS Liberté Stent for the Treatment of Long De Novo Coronary Artery Lesions

NCT00371475
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
TAXUS Liberté-SR, TAXUS™ Express
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
19
States / cities
Sacramento, California • Newark, Delaware • Orlando, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2012 · Synced Jul 25, 2026, 8:20 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Clinical Study to Evaluate the Efficacy and Safety of VR506 Using a New Inhaler for the Treatment of Asthma

NCT01720069
View directory record Official record
Conditions
Asthma
Interventions
VR506
Drug
Lead sponsor
Vectura Limited
Industry
Eligibility
12 Years to 65 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
11
States / cities
Los Angeles, California • Denver, Colorado • Celebration, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Jul 25, 2026, 8:20 AM EDT
Active, not recruiting Phase 2 Interventional

Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma)

NCT06940141
View directory record Official record
Conditions
Asthma Acute
Interventions
Rademikibart in prefilled syringe, Matching placebo in prefilled syringe
Combination Product · Drug
Lead sponsor
Connect Biopharm LLC
Industry
Eligibility
12 Years to 75 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
21
States / cities
Palo Alto, California • Valencia, California • Wilmington, Delaware + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jul 25, 2026, 8:20 AM EDT
Completed Phase 2 Interventional Results available

Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma

NCT02360579
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Lifileucel
Biological
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
23
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Jul 25, 2026, 8:20 AM EDT
Completed Phase 2 Interventional Results available

The Effect of Various Amounts of Fat on PK of Oral Testosterone Undecanoate

NCT02921386
View directory record Official record
Conditions
Hypogonadism
Interventions
Oral Testosterone Undecanoate
Drug
Lead sponsor
Clarus Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Torrance, California • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Jul 25, 2026, 8:20 AM EDT
Terminated Phase 3 Interventional

A Study to Investigate the Safety and Efficacy of LT-02 in Patients With Mesalamine Refractory Ulcerative Colitis (UC)

NCT02849951
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
LT-02, LT-02 Placebo
Drug
Lead sponsor
Prometheus Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
45
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Chula Vista, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Jul 25, 2026, 8:20 AM EDT